SY-007

SY-007 is an interfering peptide designed to disrupt the cell death signaling associated with phosphatase and tensin homolog deleted on chromosome ten (PTEN) nuclear translocation during ischemic stroke. Preclinical studies demonstrated that administration of SY-007 reduced stroke lesion size in animal models, even when given up to 6 hours after stroke onset. In first-in-human clinical trials, intravenous doses of SY-007 were well tolerated in healthy subjects, with only mild or moderate adverse events reported. The drug exhibits nonlinear pharmacokinetics likely due to target-mediated drug disposition. The primary indication under investigation is neuroprotection in patients with ischemic stroke[1][2].